Mervituxumab: A Maintenance Therapy for Ovarian Cancer

Mervituxumab is approved under an accelerated approval, and I think many people who are treating patients with recurrent ovarian cancer are trying to understand the nuances of the expectations for efficacy in these different settings. So we're really excited about this because it does provide some more clarity on the initial activity that we saw. And fortunately, what we did find was that there was pretty consistent activity even in the most highest risk patients. We still saw an objective response of almost 18%.